Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • Tolazoline: α2-Adrenergic Receptor Antagonist & K+ Channe...

    2026-02-11

    Tolazoline: Molecular Tool for α2-Adrenergic Receptor and Potassium Channel Research

    Executive Summary: Tolazoline is a dual-action imidazoline compound functioning as a selective α2-adrenergic receptor antagonist and partial ATP-sensitive potassium (K+) channel blocker in pancreatic β cells (Jonas et al., 1992). It inhibits 86Rb efflux from mouse islets by 8.1% at 10 μM and 13.7% at 100 μM, indicating partial block of ATP-sensitive K+ channels. Tolazoline reverses clonidine-induced inhibition of insulin secretion at concentrations ≥31.8 μM. The compound is used in vitro (10 nM–500 μM) and in vivo (0.12 mg/kg, IV in horses) to study α2-adrenergic and K+ channel-mediated pathways. APExBIO’s Tolazoline (SKU A8991) is supplied at ≥98% purity and is soluble in DMSO (APExBIO).

    Biological Rationale

    Tolazoline is an imidazoline derivative. It was developed to interrogate α2-adrenergic receptor pathways and ATP-sensitive K+ channel function in cell and animal models. α2-adrenergic receptors are G protein-coupled receptors (GPCRs) that mediate inhibition of neurotransmitter release and smooth muscle tone (Tolazolineapis.com). In pancreatic β cells, activation of α2-adrenergic receptors suppresses insulin secretion, which is also regulated by ATP-sensitive K+ channels. Tolazoline’s dual action allows researchers to dissect the contributions of adrenergic and K+ channel signaling to cellular function, insulin release, and airway smooth muscle tone (Jonas et al., 1992).

    Compared to other imidazoline antagonists, Tolazoline requires higher concentrations to antagonize α2-adrenergic receptors and exhibits weaker K+ channel blockade. This distinguishes its pharmacological profile and makes it suitable for selective pathway studies (Tolazolineapis.com (Mechanistic)).

    Mechanism of Action of Tolazoline

    Tolazoline acts via two principal mechanisms:

    • α2-Adrenergic Receptor Antagonism: Tolazoline competitively inhibits α2-adrenergic receptors, reducing receptor-mediated inhibition of insulin secretion and cholinergic neurotransmission. In rat cerebral cortex, the -logK value is approximately 6.80, indicating moderate affinity (Jonas et al., 1992).
    • ATP-Sensitive K+ Channel Blockade: Tolazoline partially blocks ATP-sensitive K+ channels in pancreatic β cells, leading to depolarization and enhanced insulin secretion. In vitro, it inhibits 86Rb efflux from islets, a surrogate for K+ channel activity, by 8.1% at 10 μM and 13.7% at 100 μM. Complete reversal of clonidine-induced insulin suppression requires ≥31.8 μM Tolazoline (Jonas et al., 1992).
    • Cholinergic Inhibition: By inhibiting cholinergic neurotransmitter release, Tolazoline indirectly regulates airway smooth muscle contraction and tone (Tolazolineapis.com (Islet/Airway)).

    These dual mechanisms allow Tolazoline to serve as a probe for dissecting pathway-specific contributions in both endocrine and pulmonary models. For a more detailed mechanistic comparison with next-generation derivatives, see this analysis, which focuses on structure-activity relationships and translational strategies not covered in this article.

    Evidence & Benchmarks

    • In vitro, Tolazoline inhibits 86Rb efflux from perifused mouse islets by 8.1% at 10 μM and 13.7% at 100 μM, indicating partial block of ATP-sensitive K+ channels (Jonas et al., 1992).
    • At 500 μM, Tolazoline blocks approximately 20% of ATP-sensitive K+ channel current in single β cells measured by patch-clamp (Jonas et al., 1992).
    • Reversal of clonidine-induced inhibition of insulin secretion requires Tolazoline at concentrations ≥31.8 μM (Jonas et al., 1992).
    • In vivo, intravenous Tolazoline at 0.12 mg/kg in horses blocks xylazine-induced bronchodilation (APExBIO).
    • Typical in vitro concentrations for airway smooth muscle studies are 10 nM; for islet function, 10–500 μM (APExBIO).
    • Tolazoline is ≥98% pure, soluble in DMSO, and should be stored at -20°C; solutions should be used promptly (APExBIO).

    This article extends the summary in "Tolazoline: Precision α2-Adrenergic Antagonist for Advanced Research" by providing integrated evidence benchmarks and explicit concentration-response context for translational workflows.

    Applications, Limits & Misconceptions

    Core Applications:

    • Dissection of α2-adrenergic receptor signaling in in vitro and animal models.
    • Investigation of ATP-sensitive K+ channel regulation in pancreatic β cells and insulin secretion modulation (Jonas et al., 1992).
    • Modulation of airway smooth muscle tone via cholinergic and adrenergic pathways (Tolazolineapis.com (Islet/Airway)).
    • Translational studies bridging in vitro findings to animal models of bronchodilation and diabetes (Tolazolineapis.com (Translational)).

    Common Pitfalls or Misconceptions

    • Not a Potent K+ Channel Blocker: Tolazoline exhibits weaker ATP-sensitive K+ channel block than other imidazoline derivatives (e.g., phentolamine, antazoline); it is not the best option when maximal K+ channel inhibition is required (Jonas et al., 1992).
    • Concentration Dependency: High concentrations (≥31.8 μM) are needed for full reversal of adrenergic inhibition of insulin secretion; lower doses may not achieve desired antagonism.
    • Short Solution Stability: Tolazoline solutions are unstable for long-term storage; use immediately after preparation (APExBIO).
    • Species and Tissue Variability: Efficacy and required concentrations may differ across species and tissues; always validate in the target system.
    • Not a Direct Agonist: Tolazoline does not activate adrenergic receptors or K+ channels; it antagonizes or blocks them.

    Workflow Integration & Parameters

    Preparation and Handling: Tolazoline is supplied as a solid, soluble in DMSO. Store at -20°C. Prepare fresh solutions for each experiment (APExBIO).

    • In vitro Airway Smooth Muscle Studies: Use concentrations as low as 10 nM for receptor antagonism assays (Tolazolineapis.com).
    • Islet Function Assays: Employ 10–500 μM for K+ channel and insulin secretion studies; effects are dose-dependent (Jonas et al., 1992).
    • Animal Models: Intravenous dose for blocking xylazine-induced bronchodilation in horses is 0.12 mg/kg (APExBIO).
    • Purity: The A8991 kit from APExBIO provides ≥98% purity, minimizing off-target effects (APExBIO).

    This article clarifies application concentrations and performance benchmarks beyond the scope of "Tolazoline: Advanced Insights into α2-Adrenergic Antagonism", which focuses on mechanistic insights.

    Conclusion & Outlook

    Tolazoline is an established research tool for dissecting the interplay between α2-adrenergic signaling and ATP-sensitive K+ channel activity in airway and islet models. While less potent as a K+ channel blocker than some analogs, its dual action supports integrative pharmacology and translational workflows. For the latest product specifications and ordering, see Tolazoline at APExBIO. Future research may leverage Tolazoline’s selectivity to unravel more nuanced neuroendocrine and pulmonary mechanisms, especially in disease models where adrenergic tone and insulin regulation intersect.